Share Eli Lilly (LLY) Q3 2026 Earnings Review: Diabetes and obesity demand lift sales outlook
← Stock movers news
Earnings results
Eli LillyLLY · Drug Manufacturers - General
LLY · October 29, 2026Before open · Since the previous regular close
+4.09%Session snapshot

Eli Lilly (LLY) Q3 2026 Earnings Review: Diabetes and obesity demand lift sales outlook

Earnings results

  • EPS

    Actual: $7.48 adjusted; $7.22 reported · Matching consensus not verified

  • Revenue beat 8.0%

    Actual: $24.397B · Cons.: $22.58B

  • Guidance mixed

    Sales raised to $91–92B from $85–87B; adjusted profit/share lowered to $35–36 from $35.50–36.50

By Stocks To Buy Now AI ResearchPublished

91
Exterior of Eli Lilly corporate headquarters in Indianapolis
Archive photograph of Eli Lilly corporate headquarters in Indianapolis, February 2011. Photo: Paul Sableman / Wikimedia Commons · CC BY 2.0 · Wikimedia-supplied thumbnail; displayed with a responsive crop.
THE CATALYST

What the company reported

Eli Lilly raised its sales outlook as diabetes and obesity demand lifted quarterly revenue 39%, but acquisition-related research costs reduced its profit forecast. Full-year sales guidance rose to $91–92 billion, but adjusted profit guidance fell to $35–36 per share after research deal costs.

AT A GLANCE

Q3 2026 earnings recap

Eli Lilly raised its sales outlook as diabetes and obesity demand lifted quarterly revenue 39%, but acquisition-related research costs reduced its profit forecast.

  • Third-quarter revenue of $24.4 billion exceeded the $22.58 billion consensus, with Mounjaro and Zepbound driving growth.
  • Adjusted profit per share was $7.48, including $4.57 of costs for acquired research projects, while reported profit per share was $7.22.
  • Full-year sales guidance rose to $91–92 billion, but adjusted profit guidance fell to $35–36 per share after research deal costs.
  • Volume grew 53% while realized prices fell 15%, making demand and production efficiency essential to future margins.
  • At the October 28 close of $1,288.3, shares traded at about 42 times trailing reported earnings, leaving a demanding valuation.
  • The pre-earnings chart shows support around $1,239–1,262 and recent highs near $1,312–1,322, with any breakout needing confirmation.

Watch whether stronger demand offsets pricing pressure as roughly $900 million of quarterly revenue benefits makes growth harder to repeat.

THE VISUAL RESEARCH

Financials, technicals and earnings

Charts through Oct 28, 2026.

Financials
Technicals
Earnings & peers
WHAT TO WATCH

Technical setup and risks

The October 28 close remains above the 20- and 50-day averages; a sustained move above $1,322 would strengthen momentum, while a close below $1,239 would weaken it. Lower prices and acquisition costs remain risks.

AI-assisted earnings research with verified issuer results. Charts use the stated completed session. Educational information; investing involves risk.

EXPLORE COMPANY RESEARCH

Eli Lilly and: the full stock picture

Earnings history, financials, price action and peer comparisons — all below.
Open LLY stock page ↗

EXPLORE THE COMPANY

Eli Lilly and (LLY)

Explore earnings, price action, financials and industry comparisons.

Symbol
LLY
Sector
Healthcare
Industry
Drug Manufacturers - General
Instrument type
EQUITY

Profile information from our saved company catalog. This is not a live quote or confirmation of current listing status.

EARNINGS & COMPANY RESEARCH

LLY earnings, valuation & price action

View in calendar ↗
NEXT EXPECTED REPORTOct 29 2026Before open · ET
EPS ESTIMATE5.68
REVENUE ESTIMATE22.58B

Expected dates may change. Estimates use the source’s reporting currency. Quotes and research are snapshots, not live prices.

COMPANY RESEARCH · Healthcare

Eli Lilly and Company LLY

Drug Manufacturers - General · Updated 10/26/2026

Adjusted closing price · USD1,279.14 Oct 26
74594111371333Oct 23Apr 27Oct 26
Price50-day average200-day average+56.8% in view
VALUATION & EXPECTATIONS
Trailing P/E41.8×
Forward P/E37.0×
Trailing P/S14.8×
Forward P/S13.3×
EPS beat rate88%
Revenue beat rate86%
Positive window63%

EPS beats: 7 of 8 comparable reports. Positive price windows: 5 of 8.

Market caps may be up to 14 days old; prices up to seven days old; ratios and analyst estimates up to fourteen days old. Forward multiples use consensus for the fiscal year ending 2026-12-31, not the next 12 months. Negative or unavailable earnings multiples show “N/A”. Forward ADR multiples are omitted when the currency/share basis is not reconciled.

50-day average1,188.58
200-day average1,083.84
RSI (14)63
20-day range1,142.85 – 1,306.69
Relative volume0.9×
1-year change+56.8%
Last eight reported earnings for LLY
Report dateEPS estimateEPS actualSurpriseResultRevenue actualPrice window*5 sessions*
Aug 5 20266.408.38+30.9%Beat22.97B+6.8%+9.4%
Apr 30 20266.978.55+22.7%Beat19.8B+13.2%+14.5%
Feb 4 20266.917.54+9.1%Beat19.29B+1.7%+1.2%
Oct 30 20255.697.02+23.4%Beat17.6B+6.1%+15.2%
Aug 7 20255.606.31+12.7%Beat15.56B-16.2%-8.3%
May 1 20253.263.34+2.5%Beat12.73B-8.4%-16.4%
Feb 6 20255.035.32+5.8%Beat13.53B+4.3%+3.5%
Oct 30 20241.471.18-19.7%Miss11.44B-8.2%-14.1%

*Adjusted close before the report date to the first (or fifth) trading close after it. This window can span two sessions and is not an isolated earnings-day return. Figures may be revised by the provider.

More LLY research Data,

LLY earnings previews and market catalysts

Earnings week of October 26–30, 2026: cloud growth, consumers and cash flow
2026-10-25 · Microsoft, Alphabet and Amazon lead a busy earnings week. Follow twelve major reports across payments, medicine, energy and consumer goods, with the key business questions and risks to watch.

Eli Lilly (LLY) Earnings October 29, 2026: Estimates, Drug Sales and Guidance
2026-10-22 · Lilly’s October 29 earnings call puts diabetes and obesity drug sales, pricing, acquired research charges and guidance in focus. Review estimates, prior results and a recent pharmaceutical peer.

All upcoming earnings catalysts →

02 / FINANCIALS

Eli Lilly and financials

Revenue, earnings, cash flow and financial strength in one view.

Reporting currency unconfirmed.

Revenue
Net income
Gross profit
Operating income
EBITDA
Operating cash flow
Capital expenditure
Cash
Total assets
Total liabilities
Shareholder equity
Total debt
Net profit margin
Gross margin
Short interest: days to cover
How to read these financial metrics

Figures use the app’s saved statements for the displayed period, not a trailing-year total. Margins divide profit by revenue; quick ratio uses current assets less inventory divided by current liabilities. Compare dates and currencies before comparing companies.

03 / WHAT COMES NEXT

Eli Lilly and event catalysts

Company earnings and scheduled market events that may change expectations.

2026-10-29

LLY earnings

Watch reported results, management’s outlook and the share-price reaction.

See earnings expectations ↑
2026-10-298:30 AM ET

Initial jobless claims

Use the multiweek trend to distinguish normal volatility from a sustained increase in layoffs.

Release schedule ↗Scheduled
2026-10-298:30 AM ET

PCE inflation & consumer spending

Compare core PCE and real spending with expectations to assess inflation alongside demand.

Release schedule ↗Scheduled
2026-10-298:30 AM ET

Q3 GDP · advance estimate

Separate consumer demand from inventory and trade effects; revisions can change the growth picture.

Release schedule ↗Scheduled
2026-10-308:30 AM ET

Employment Cost Index

Persistent compensation pressure can affect margins and the inflation outlook.

Release schedule ↗Scheduled
2026-10-30Market close

Russell indexes · rank day

A ranking checkpoint, not an announcement that a particular stock has been included.

Release schedule ↗Scheduled
2026-11-0210:00 AM ET

ISM manufacturing PMI

Watch new orders and prices paid for the balance between demand and inflation.

Release schedule ↗Scheduled
2026-11-0310:00 AM ET

JOLTS job openings

Watch vacancies and quits for signs of labor-market cooling.

Release schedule ↗Scheduled
2026-11-0410:00 AM ET

ISM services PMI

Services prices and employment can influence the outlook for inflation and rates.

Release schedule ↗Scheduled

Dates use U.S. Eastern time and can change. Calendar events provide context; they do not determine the direction of a stock move.

04 / SIDE BY SIDE

Compare LLY with its peers

Drug Manufacturers - General · Compare valuation, financial strength and price performance.

Companies with valuation data7
Peer median positive P/E27.9×
LLY P/E41.8×
LLY peer comparison: valuation
CompanyPriceMarket capP/EForward P/EP/SForward P/S
LLYEli Lilly and2026-10-26 · USD1,279.141.18T41.8×37.0×14.8×13.3×
ABBVAbbVie Inc.2026-10-26 · USD286.74504.37B80.4×20.6×7.8×7.5×
AMGNAmgen Inc.2026-10-20 · USD438.94237.31B27.1×19.1×6.2×6.1×
AZNAstraZeneca PLC2026-10-27 · USD170.36256.53B24.5×4.2×
JNJJohnson & Johnson2026-10-20 · USD259.36599.12B28.7×23.2×6.1×5.9×
MRKMerck & Co., Inc.2026-10-23 · USD144.98368.87B118.7×54.7×5.6×5.5×
NVONovo Nordisk A/S2026-10-23 · USD39.05174.65B10.1×3.5×
LLY41.8×
ABBV80.4×
AMGN27.1×
AZN24.5×
JNJ28.7×
MRK118.7×
NVO10.1×

The peer median excludes the selected stock and is based on 6 available positive multiples. P/E median excludes negative or missing earnings multiples. Peer reports can have different fiscal periods and currencies; values are not currency-converted.

05 / PEER ANALYSIS

Explore LLY alongside its peers

Drug Manufacturers - General · 15 companies · Cached market data

Comparison

Compare companies

Tap a bubble to inspect a company, then × to hide it. Undo restores the last company hidden. Bubble area reflects market cap, with a minimum size for visibility.

Price / sales
1.2×51.12B6.2×466.16B11.2×881.2B16.2×1.3TJNJ · Johnson & Johnson Market cap: 599.12B Price / sales: 6.1×ABBV · AbbVie Market cap: 504.37B Price / sales: 7.8×MRK · Merck & Market cap: 368.87B Price / sales: 5.6×NVS · Novartis AG Market cap: 285.49B Price / sales: 5.2×AZN · AstraZeneca Market cap: 256.53B Price / sales: 4.2×AMGN · Amgen Market cap: 237.31B Price / sales: 6.2×GILD · Gilead Sciences Market cap: 194.07B Price / sales: 6.4×NVO · Novo Nordisk A/S Market cap: 174.65B Price / sales: 3.5×PFE · Pfizer Market cap: 171.62B Price / sales: 2.7×LLY · Eli Lilly and Company Market cap: 1.18T Price / sales: 14.8×Hide LLY · Undo restores itMarket cap
LLYEli Lilly and Company

Market cap: 1.18T
Price / sales: 14.8×

Valuation snapshot: 2026-10-26
View research ↗
10 of 15 companies have both plotted values.

P/S distribution

Trailing price-to-sales multiples · 10 companies

Median P/S5.8×
Middle 50%4.4× to 6.3×
LLY P/S14.8×
2.4×8.2×

Tap a bar to see the companies in that P/S range. LLY has a higher P/S than 90% of this group.

5 companies excluded from P/S statistics because sales are non-positive or the saved multiple is missing. Statistics include all valid positive values, including those outside the focused chart range.

Companies

Showing 8 of 15 matching companies · Largest market cap first

  • Market cap 1.18TP/E 41.8×P/S 14.8×Forward P/E Forward P/S Price snapshot: 2026-10-26
    ↗
  • Market cap 599.12BP/E 28.7×P/S 6.1×Forward P/E Forward P/S Price snapshot: 2026-10-20
    ↗
  • Market cap 504.37BP/E 80.4×P/S 7.8×Forward P/E Forward P/S Price snapshot: 2026-10-26
    ↗
  • Market cap 368.87BP/E 118.7×P/S 5.6×Forward P/E Forward P/S Price snapshot: 2026-10-23
    ↗
  • Market cap 285.49BP/E 22.8×P/S 5.2×Forward P/E Forward P/S Price snapshot: 2026-10-26
    ↗
  • Market cap 256.53BP/E 24.5×P/S 4.2×Forward P/E Forward P/S Price snapshot: 2026-10-27
    ↗
  • Market cap 237.31BP/E 27.1×P/S 6.2×Forward P/E Forward P/S Price snapshot: 2026-10-20
    ↗
  • Market cap 194.07BP/E P/S 6.4×Forward P/E Forward P/S Price snapshot: 2026-10-28
    ↗

Explore industries

Open an industry for its comparison, valuation and companies.

U.S.-listed companies from the app’s catalog. Medians use saved positive P/E values; coverage and snapshot dates vary.

How this comparison works

Uses the saved companies from the same industry and listing market, including LLY, ordered by cached market cap. Company snapshots can have different dates; the web cache may cover fewer metrics and periods than the app.

Periods end at each company’s dated price snapshot. Change compares the latest saved observation with one at or before the selected period’s start. A daily price change uses consecutive saved sessions. Financial data updates quarterly, so short periods may show no change. Missing history and zero starting values are excluded; a negative starting value uses its absolute value as the denominator.

Metrics use saved ratios and percentages. Market caps use the listing market’s reporting currency; underlying financial statements may use different currencies. Circle sizes have a minimum for touch visibility, and an outlined circle indicates a missing market cap. These comparisons describe data, not recommendations or price predictions.

Related research

Company research, movers, earnings and options results.

INDUSTRY COMPARISON

LLY industry peers

Drug Manufacturers - General · Oct 16, 2026 · Closing-price performance

Compare LLY with 7 other stocks in the available heatmap coverage.

JNJJohnson & Johnson+0.90%ABBVAbbVie Inc.+0.71%MRKMerck & Co., Inc.+0.52%PFEPfizer Inc.+0.48%LLYCurrent stockEli Lilly and Company+0.43%AMGNAmgen Inc.-0.35%GILDGilead Sciences, Inc.-0.75%BMYBristol-Myers Squibb Company-1.35%